 NEW YORK, Jan. 19, 2023 GLOBE NEWSWIRE Kaplan Fox Kilsheimer LLP is continuing its investigation of claims on behalf of investors in Y-mAbs Therapeutics, Inc. Y-mAbs or the Company NASDAQ: YMAB stock. A complaint has been filed on behalf of investors who purchased shares of Y-mAbs common stock on the open market, ... The post Y-mAbs Therapeutics, Inc. NASDAQ: YMAB Investor Alert: Kaplan Fox Kilsheimer LLP Notifies Y-mAbs Investors of a Class Action Lawsuit a... 